Cantor Fitzgerald Lowers Endo International (NASDAQ:ENDP) Price Target to $7.00

Endo International (NASDAQ:ENDP) (TSE:ENL) had its price target lowered by Cantor Fitzgerald from $9.00 to $7.00 in a research note released on Friday, November 10th. Cantor Fitzgerald currently has a neutral rating on the stock.

Several other analysts have also commented on the company. Citigroup dropped their target price on Endo International from $9.00 to $7.00 and set a neutral rating on the stock in a report on Friday, November 10th. Royal Bank Of Canada dropped their target price on Endo International from $9.00 to $8.00 and set a sector perform rating on the stock in a report on Friday, November 10th. Zacks Investment Research lowered Endo International from a hold rating to a sell rating in a report on Thursday, October 26th. ValuEngine raised Endo International from a hold rating to a buy rating in a report on Monday, October 2nd. Finally, Goldman Sachs Group began coverage on Endo International in a report on Thursday, September 28th. They issued a sell rating and a $7.00 price objective on the stock. Four investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of Hold and a consensus target price of $11.67.

Endo International (NASDAQ ENDP) traded up $0.25 during trading on Friday, reaching $7.48. The company’s stock had a trading volume of 4,020,200 shares, compared to its average volume of 7,228,586. The company has a debt-to-equity ratio of 10.78, a quick ratio of 0.86 and a current ratio of 1.08. Endo International has a 52 week low of $5.77 and a 52 week high of $17.99. The stock has a market capitalization of $1,610.00, a PE ratio of 1.56, a PEG ratio of 2.05 and a beta of 0.53.

Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings data on Thursday, November 9th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.06. Endo International had a positive return on equity of 66.98% and a negative net margin of 126.97%. The firm had revenue of $786.90 million during the quarter, compared to analysts’ expectations of $794.93 million. During the same period last year, the business posted $1.01 earnings per share. The company’s revenue for the quarter was down 11.0% compared to the same quarter last year. equities research analysts predict that Endo International will post 3.67 EPS for the current fiscal year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Cornerstone Capital Management Holdings LLC. boosted its position in shares of Endo International by 64.0% during the 3rd quarter. Cornerstone Capital Management Holdings LLC. now owns 135,627 shares of the company’s stock worth $1,160,000 after acquiring an additional 52,927 shares in the last quarter. LMR Partners LLP acquired a new position in shares of Endo International during the 3rd quarter worth about $148,000. Van ECK Associates Corp boosted its position in shares of Endo International by 67.1% during the 3rd quarter. Van ECK Associates Corp now owns 340,991 shares of the company’s stock worth $2,921,000 after acquiring an additional 136,873 shares in the last quarter. Alps Advisors Inc. boosted its position in shares of Endo International by 9.3% during the 3rd quarter. Alps Advisors Inc. now owns 250,511 shares of the company’s stock worth $2,146,000 after acquiring an additional 21,373 shares in the last quarter. Finally, Gamco Investors INC. ET AL boosted its position in shares of Endo International by 76.2% during the 3rd quarter. Gamco Investors INC. ET AL now owns 110,500 shares of the company’s stock worth $946,000 after acquiring an additional 47,800 shares in the last quarter. 93.17% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by BBNS and is owned by of BBNS. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://baseballnewssource.com/markets/endo-international-plc-endp-price-target-cut-to-7-00/1775685.html.

Endo International Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with our FREE daily email newsletter.

 


Latest News

Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees


Leave a Reply

 
© 2006-2017 BBNS.